The fast pace of innovation in IT offers compelling investment opportunities
Truffle Capital is a pioneer investor in the exciting field of Energy
Biotechnology has radically transformed medicine over the past 25 years
Splicos SAS is a Montpellier based academic spin off from two CNRS institutes: IGMM (Molecular Genetics Institute of Montpellier) and CRBM (Macromolecular Biochemistry Research Center of Montpellier), which have developed breakthrough technologies in the fields of alternative splicing and metastatic migration. Splicos’ business model is to generate therapeutical leads in the cancer, HIV, genetic diseases and then to nurture them into potential “drug candidates”.
Truffle Capital invested in Splicos in 2008 and is Splicos’ majority shareholder.
Truffle Capital board member: Dr. Philippe Pouletty